Here are three updates on GI companies to note:
After reporting non-statistically significant results in a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile treatment.
A Spherix Global Insights report found Janssen Pharmaceuticals' Stelara, an alternative mechanism biologic, was the most exciting advancement to happen to inflammatory bowel disease in 2016.
The FDA issued a communication claiming Viberzi — a medicine used for patients with irritable bowel syndrome with diarrhea — could increase pancreatitis risk in patients without gallbladders. Parsippany-Troy Hills, N.J.-based Allergan manufactures the drug. The FDA and Allergan are addressing potential safety concerns.